ABBV
Abbvie·NYSE
--
--(--)
--
--(--)
ABBV fundamentals
Abbvie (ABBV) released its earnings on Feb 4, 2026: revenue was 16.62B (YoY +10.04%), beat estimates; EPS was 2.71 (YoY +25.46%), beat estimates.
Revenue / YoY
16.62B
+10.04%
EPS / YoY
2.71
+25.46%
Report date
Feb 4, 2026
ABBV Earnings Call Summary for Q4,2025
- Revenue Growth: 8.6% YoY to $61.2B, driven by Skyrizi/Rinvoq ($25.9B) and Vyalev launch. 2026 guidance: $67B (9.5% growth).
- Pipeline Momentum: 90+ clinical programs, $5B+ BD investments (CAR-T, psychedelics, oncology). Rinvoq Phase III in HS and alopecia areata expected Q2 2026.
- Financial Strength: 2026 free cash flow $18.5B, supporting 330%+ dividend growth since 2013. Gross margin >84%, R&D spend $9.7B.
- Strategic Wins: U.S. government agreement protects innovation while improving access. Parkinson's franchise on track for $5B+ peak with Vyalev and tavapadon.
EPS
Actual | 2.42 | 2.34 | 2.83 | 2.92 | 2.95 | 3.11 | 3.33 | 3.31 | 3.16 | 3.37 | 3.66 | 3.6 | 2.46 | 2.91 | 2.95 | 2.79 | 2.31 | 2.65 | 3 | 2.16 | 2.46 | 2.97 | 1.86 | 2.71 | ||||||||||||||||
Forecast | 2.2457 | 2.1962 | 2.7596 | 2.8525 | 2.8069 | 3.0815 | 3.2137 | 3.2834 | 3.1416 | 3.3205 | 3.5732 | 3.561 | 2.5088 | 2.832 | 2.8677 | 2.793 | 2.2545 | 2.5656 | 2.9199 | 2.1152 | 2.3793 | 2.8801 | 1.7657 | 2.6529 | ||||||||||||||||
Surprise | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | +7.76% | +6.55% | +2.55% | +2.37% | +5.10% | +0.92% | +3.62% | +0.81% | +0.59% | +1.49% | +2.43% | +1.10% | -1.95% | +2.75% | +2.87% | -0.11% | +2.46% | +3.29% | +2.74% | +2.12% | +3.39% | +3.12% | +5.34% | +2.15% |
Revenue
Actual | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 8.62B | 10.43B | 12.90B | 13.86B | 13.01B | 13.96B | 14.34B | 14.89B | 13.54B | 14.58B | 14.81B | 15.12B | 12.22B | 13.87B | 13.93B | 14.30B | 12.31B | 14.46B | 14.46B | 15.10B | 13.34B | 15.42B | 15.78B | 16.62B |
Forecast | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 8.33B | 9.94B | 12.72B | 13.70B | 12.77B | 13.63B | 14.30B | 14.95B | 13.61B | 14.66B | 14.96B | 15.33B | 12.17B | 13.54B | 13.72B | 14.03B | 11.93B | 14.02B | 14.28B | 14.83B | 12.93B | 15.03B | 15.59B | 16.41B |
Surprise | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | +3.53% | +4.89% | +1.45% | +1.18% | +1.90% | +2.40% | +0.31% | -0.44% | -0.55% | -0.56% | -0.99% | -1.37% | +0.48% | +2.41% | +1.52% | +1.97% | +3.19% | +3.14% | +1.24% | +1.82% | +3.22% | +2.62% | +1.22% | +1.25% |
Earnings Call
You can ask Aime
What does Abbvie do and what are its main business segments?What is the market's earnings forecast for Abbvie next quarter?What were the key takeaways from Abbvie’s earnings call?What factors drove the changes in Abbvie's revenue and profit?Did Abbvie beat or miss consensus estimates last quarter?What is the revenue and EPS growth rate for Abbvie year over year?What guidance did Abbvie's management provide for the next earnings period?What is Abbvie's latest dividend and current dividend yield?
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
